OBJECTIVE: We sought to evaluate population gestational diabetes mellitus (GDM) screening results and risk for incident insulin treatment. STUDY DESIGN: Among 64,687 pregnant women universally screened for GDM from 1995 through 2010 in 2 regions of a large US health plan, we stratified women requiring insulin treatment during their pregnancy by GDM screening results (50-g glucose challenge test [GCT]), followed by a 3-hour, 100-g oral glucose tolerance test if GCT was positive. Women with GCT >200 mg/dL were evaluated separately. RESULTS: Overall, 2% of all pregnant women required insulin treatment, ranging from 0.1% (normal GCT) to 49.9% (GCT >200 mg/dL; P for trend < .0001). Women with GCT >200 mg/dL had a much higher rate of insulin treatment than women with GDM (odds ratio, 3.7; 95% confidence interval, 3.1-4.4). Risk factors for higher insulin treatment rates with GDM or GCT >200 mg/dL included obesity, race/ethnicity, and diagnosed ≤16 weeks' gestation. CONCLUSION: Our results indicate women with GCT >200 mg/dL could be reasonably treated as GDM without requiring additional oral glucose tolerance test for diagnosis.
OBJECTIVE: We sought to evaluate population gestational diabetes mellitus (GDM) screening results and risk for incident insulin treatment. STUDY DESIGN: Among 64,687 pregnant women universally screened for GDM from 1995 through 2010 in 2 regions of a large US health plan, we stratified women requiring insulin treatment during their pregnancy by GDM screening results (50-g glucose challenge test [GCT]), followed by a 3-hour, 100-g oral glucose tolerance test if GCT was positive. Women with GCT >200 mg/dL were evaluated separately. RESULTS: Overall, 2% of all pregnant women required insulin treatment, ranging from 0.1% (normal GCT) to 49.9% (GCT >200 mg/dL; P for trend < .0001). Women with GCT >200 mg/dL had a much higher rate of insulin treatment than women with GDM (odds ratio, 3.7; 95% confidence interval, 3.1-4.4). Risk factors for higher insulin treatment rates with GDM or GCT >200 mg/dL included obesity, race/ethnicity, and diagnosed ≤16 weeks' gestation. CONCLUSION: Our results indicate women with GCT >200 mg/dL could be reasonably treated as GDM without requiring additional oral glucose tolerance test for diagnosis.
Authors: Yvonne W Cheng; Tania F Esakoff; Ingrid Block-Kurbisch; Alla Ustinov; Sherri Shafer; Aaron B Caughey Journal: J Matern Fetal Neonatal Med Date: 2006-11
Authors: Mark B Landon; Catherine Y Spong; Elizabeth Thom; Marshall W Carpenter; Susan M Ramin; Brian Casey; Ronald J Wapner; Michael W Varner; Dwight J Rouse; John M Thorp; Anthony Sciscione; Patrick Catalano; Margaret Harper; George Saade; Kristine Y Lain; Yoram Sorokin; Alan M Peaceman; Jorge E Tolosa; Garland B Anderson Journal: N Engl J Med Date: 2009-10-01 Impact factor: 91.245
Authors: Tania Pertot; Lynda Molyneaux; Kris Tan; Glynis P Ross; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2011-08-11 Impact factor: 19.112
Authors: Teresa A Hillier; Kathryn L Pedula; Keith K Ogasawara; Kimberly K Vesco; Caryn Oshiro; Jan L Van Marter Journal: J Perinat Med Date: 2022-05-11 Impact factor: 2.716
Authors: Teresa A Hillier; Keith K Ogasawara; Kathryn L Pedula; Kimberly K Vesco; Caryn E S Oshiro; Jan L Van Marter Journal: J Womens Health (Larchmt) Date: 2020-04-24 Impact factor: 2.681
Authors: Elizabeth W Dehmer; Milind A Phadnis; Erica P Gunderson; Cora E Lewis; Kirsten Bibbins-Domingo; Stephanie M Engel; Michele Jonsson Funk; Holly Kramer; Abhijit V Kshirsagar; Gerardo Heiss Journal: Am J Kidney Dis Date: 2017-11-08 Impact factor: 11.072
Authors: Teresa A Hillier; Kathryn L Pedula; Keith K Ogasawara; Kimberly K Vesco; Caryn E S Oshiro; Suzanne L Lubarsky; Jan Van Marter Journal: N Engl J Med Date: 2021-03-11 Impact factor: 176.079
Authors: Erin S LeBlanc; Ning X Smith; Kimberly K Vesco; Teresa A Hillier; Victor J Stevens Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134